



October 1, 2021

Announcement of Global Health Collaboration with Eisai Co., Ltd.

MicroBiopharm Japan Co., Ltd. (Headquarters: Tokyo, CEO: Akito Umeda) announced that it has concluded a collaboration agreement with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") to utilize its microbial-derived compounds and fermentation-related technologies in support of Eisai's global health initiatives aimed at improving access to medicines for infectious diseases in emerging and developing countries.

As the company whose mission is to contribute to healthier and higher-quality life of people throughout the world by providing pharmaceuticals and other advanced products and services, taking advantage of our distinctive microbiological expertise and technologies, we are committed to addressing to the solution of social issues related to global health.

【About MicroBiopharm Japan Co., Ltd.】

Based on the fermentation and microbial specialized technologies, including bioconversion, that we have cultivated and been developing for more than 70 years, we combine them with organic synthesis and other technologies to create new value as a "specialty biotech CDMO" and provide products and services including pharmaceuticals at various stages from R&D to commercial manufacturing.

WebURL: <https://www.microbiopharm.com/en/index.html>

【About Eisai's Efforts to Improve Access to Medicines】

The proactive efforts toward developing medicines that address clear needs in developing countries, such as treatments for neglected tropical diseases (NTDs) and three major infectious diseases (malaria, tuberculosis and HIV/AIDS), are required to improve access to medicines, even though pharmaceutical companies in developed countries have not focused on those diseases so far. Eisai is working on various activities in order to deliver its medicines to more patients and people at risk around the world including developing countries without delay.

WebURL: <https://www.eisai.com/sustainability/atm/index.html>

For inquiries regarding this announcement, please contact:

MicroBiopharm Japan Co., Ltd.

Research & Development Division, Attention: Kunihiro Toyoda

TEL: +81-52-401-1763 Inquiry form : <https://www.microbiopharm.com/en/contact/index.html>